Manufacturing and logistics
Producing RLT at scale is a precise and time-sensitive process. We continue to expand our global manufacturing footprint to help bring RLT to as many eligible patients as possible across the UK and worldwide. Explore our dedicated page to learn more about how we keep our RLT service running across the globe.
A stable and robust supply chain
Providing supply and just-in-time delivery, powered by our global manufacturing footprint, means more eligible patients receive treatment when they need it.
To ensure uninterrupted and timely production, we secure a steady supply of raw materials well in advance.
Manufacturing expertise at every step
Our meticulous production process features multiple safeguards to ensure reliable delivery of our products, meeting high quality standards.
The approval of primary and backup supply points to produce for each country of operation
The implementation of dose redundancy minimises patient impact in case of disruption
Our global manufacturing helps bring RLT to eligible patients across the world
We continue to expand our manufacturing footprint to ensure as many eligible patients as possible can receive RLT when they need it. We currently have facilities across Europe and the US, with plans to launch two new facilities in Asia.
Delivery of RLT
Discover more about the science of RLT
Watch the video below to learn more about our state-of-the-art manufacturing facility
With your partnership, we are dedicated to enhancing and refining our services to ensure more eligible patients have access to RLT.
Explore more about RLT services
RLT, radioligand therapy.
UK | March 2026 | FA-11482959
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
